The transformation of normal cells to cancer cells is tightly linked to alterations in signaling cascades that control cell proliferation, differentiation and motility. The research in our laboratory focuses a signaling axis that is deregulated in more than 30% of human cancers due to the mutational activation of the GTP-binding protein Ras. We are interested in defining the contribution of specific molecular perturbations in this signaling axis to cancer initiation and progression with the ultimate goal of utilizing this information for the development of novel diagnostic and therapeutic strategies. Ongoing projects in the laboratory include the development of cell- and animal-based models to study the role of inflammation in Ras-driven tumorigenesis, the characterization of feedback mechanisms that control the functional output of the Ras signaling axis and the use of chemical biology approaches to identify new modalities for therapeutic targeting.
Professor, Department of Biochemistry and Molecular Pharmacology
Professor, Department of Medicine
Senior Vice President and Vice Dean for Science, Chief Scientific Officer
PhD from State University of New York at Stony Brook
Cold Spring Harbor perspectives in medicine. 2017 Dec 11; ?-?
Cell reports. 2017 Jul 18; 20(3):558-571
A phase Ib study combining irinotecan with AZD1775, a selective WEE 1 kinase inhibitor, in RAS/RAF mutated metastatic colorectal cancer patients who progressed on first line therapy [Meeting Abstract]
Journal of clinical oncology. 2017 Jun 20; Conference:(2017):
Journal of cell biology. 2017 Jun 15; 216(8):2329-2338
Cancer immunology research. 2017 Jan 20; 5(3):182-190
Stress Granules in Pancreatic Cancer: Drug Resistance & Treatment
Oncology times. 2017; 39(4):30-34
PLoS one. 2016 Dec 28; 11(12):e0168984-e0168984e0168984
Nature medicine. 2016 Dec 26; 23(2):235-241